◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CAI

Caris Life Sciences, Inc. Common Stock (CAI) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-15

Caris Life Sciences, Inc. Common Stock (CAI) operates in the BIOTECHNOLOGY industry and is headquartered in Irving, United States with about 1,846 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2025-12-31, CAI reported $812M in revenue and ($538M) in net income.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.

Interactive charts & full statements → Open the CAI valuation workbench →

CAI Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31
Total Revenue	$990M	$812M	$412M	$306M	$258M	$294M	$417M	$432M	$348M	$294M	$250M	$228M	$212M	$174M	$126M	$78M	$65M	$83M	$65M	$19M	$62M
Gross Profit	$690M	$539M	$179M	$89M	$80M	$184M	$201M	$214M	$169M	$137M	$126M	$150M	$145M	$126M	$120M	$72M	$57M	$78M	$61M	$17M	$62M
Gross Margin %	69.7%	66.4%	43.4%	29.2%	31.0%	62.6%	48.1%	49.4%	48.6%	46.7%	50.4%	65.7%	68.4%	72.2%	95.6%	92.1%	86.6%	94.1%	93.8%	93.7%	100.0%
Operating Income (EBIT)	$153M	$45M	($257M)	($320M)	($316M)	$139M	$130M	$149M	$106M	$66M	$68M	$97M	$101M	$91M	$64M	$37M	$23M	$44M	$40M	$12M	$24M
Operating Margin %	15.4%	5.6%	-62.4%	-104.4%	-122.2%	47.3%	31.3%	34.4%	30.3%	22.4%	27.3%	42.6%	47.7%	52.1%	51.1%	47.4%	35.0%	53.3%	61.6%	64.7%	39.2%
Net Income	$104M	($538M)	($282M)	($341M)	($321M)	$28M	$31M	$79M	$72M	$6M	$27M	$60M	$64M	$63M	$50M	$28M	$14M	($27M)	$19M	$5M	$10M
Net Margin %	10.5%	-66.2%	-68.4%	-111.5%	-124.1%	9.4%	7.4%	18.2%	20.7%	2.0%	10.8%	26.5%	30.1%	36.5%	39.9%	36.4%	20.8%	-32.4%	29.6%	28.1%	16.2%
EBITDA	$173M	$11M	($183M)	($261M)	($246M)	$254M	$248M	$283M	$224M	$159M	$181M	$182M	$175M	$152M	$113M	$60M	$41M	$11M	$52M	$15M	$39M
Earnings Per Share (EPS)	$0.36	$-1.86	$-1.11	$-1.34	$-1.26	$1.55	$1.72	$3.97	$3.68	$0.31	$1.28	$2.85	$2.82	$3.18	$2.55	$1.56	$0.76	$-1.55	$1.15	$0.25	$0.47
Shares Outstanding (M)	283M	290M	255M	255M	255M	18M	18M	20M	20M	19M	21M	21M	23M	20M	20M	18M	18M	17M	17M	21M	21M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAI Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$264M	$216M	$293M	$217M	$181M	$121M	$130M	$102M
Gross Profit	$180M	$141M	$221M	$148M	$114M	$57M	$71M	$44M
Gross Margin %	68.1%	65.4%	75.4%	68.0%	62.7%	47.2%	54.4%	43.7%
Operating Income (EBIT)	$27M	$5M	$88M	$33M	$18M	($58M)	($37M)	($61M)
Operating Margin %	10.2%	2.4%	30.2%	15.0%	9.9%	-47.9%	-28.5%	-59.9%
Net Income	($1M)	($1M)	$82M	$24M	($72M)	($103M)	($37M)	($68M)
Net Margin %	-0.2%	-0.2%	28.0%	11.2%	-39.6%	-84.8%	-28.4%	-66.6%
EBITDA	$15M	$17M	$98M	$43M	($46M)	($83M)	($28M)	($50M)
Earnings Per Share (EPS)	$-0.00	$-0.00	$0.28	$0.08	$-0.26	$-0.40	$-0.13	$-0.24
Shares Outstanding (M)	283M	283M	290M	297M	276M	255M	281M	281M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAI Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31
Cash from Operations (CFO)	$168M	$83M	($245M)	($276M)	($286M)	$277M	$254M	$180M	$155M	$129M	$147M	$140M	$124M	$107M	$72M	$42M	$31M	$27M	$0M	$8M	$29M
Capital Expenditures (CapEx)	$44M	$16M	$8M	$22M	$42M	$219M	$319M	$813M	$502M	$251M	$389M	$307M	$312M	$525M	$492M	$207M	$31M	$204M	$220M	$46M	$0M
Free Cash Flow (FCF)	$124M	$67M	($254M)	($298M)	($328M)	$58M	($65M)	($633M)	($347M)	($122M)	($242M)	($168M)	($188M)	($418M)	($420M)	($164M)	($1M)	($177M)	($220M)	($37M)	$29M
FCF Margin %	12.5%	8.2%	-61.5%	-97.5%	-126.9%	19.6%	-15.6%	-146.5%	-99.6%	-41.4%	-97.0%	-73.7%	-88.5%	-240.2%	-334.0%	-211.1%	-0.9%	-212.7%	-339.0%	-201.4%	47.2%
Dividends Paid	—	—	—	—	—	$18M	$9M	$3M	—	—	—	—	—	—	—	—	—	—	$1M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAI Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$28M	$33M	$45M	$62M	$7M	($31M)	($39M)	($69M)
Capital Expenditures (CapEx)	$22M	$10M	$5M	$7M	$1M	$3M	$2M	$2M
Free Cash Flow (FCF)	$6M	$23M	$40M	$55M	$6M	($34M)	($41M)	($71M)
FCF Margin %	2.3%	10.4%	13.6%	25.5%	3.2%	-28.1%	-31.7%	-70.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAI Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31
Total Assets	$1.2B	$1.1B	$344M	$413M	$717M	$2.6B	$2.9B	$3.0B	$2.4B	$2.1B	$2.0B	$1.8B	$1.7B	$1.4B	$953M	$613M	$374M	$413M	$359M	$283M	$181M
Cash & Cash Equivalents	$691M	$798M	$64M	$56M	$107M	$54M	$46M	$45M	$35M	$46M	$53M	$54M	$46M	$18M	$14M	$14M	$14M	$29M	$8M	$20M	$8M
Total Liabilities	$638M	$548M	$2.8B	$2.6B	$2.4B	$1.9B	$2.2B	$2.3B	$1.9B	$1.6B	$1.5B	$1.4B	$1.3B	$1.0B	$705M	$416M	$245M	$299M	$228M	$255M	$148M
Total Debt (Short + Long-Term)	$400M	$379M	$385M	$173M	$227M	$183M	$218M	$311M	$132M	$96M	$172M	$204M	$76M	$63M	$30M	$29M	$5M	$5M	$0M	$6M	$1M
Total Shareholders' Equity	$592M	$577M	($2.5B)	($2.1B)	($1.7B)	$702M	$693M	$701M	$564M	$458M	$460M	$442M	$415M	$347M	$230M	$180M	$129M	$114M	$131M	$28M	$33M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CAI viewer.

Other Companies in BIOTECHNOLOGY

CRNX · Crinetics Pharmaceuticals Inc — $9 billion
IBRX · Immunitybio Inc — $9 billion
TGTX · TG Therapeutics Inc — $9 billion
PCVX · Vaxcyte Inc — $9 billion
PRAX · Praxis Precision Medicines Inc — $8 billion
SYRE · Spyre Therapeutics Inc. — $8 billion
IMVT · Immunovant Inc — $8 billion
IONS · Ionis Pharmaceuticals Inc — $7 billion

← CAH All “C” companies CAIE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.